A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.
The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regimen using a canarypox vector and an HIV envelope protein with alum, as shown in the RV144 trial. Since the efficacy was weak, and previous HIV vaccine trials designed to generate antibody responses fai...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Acceso en liña: | http://europepmc.org/articles/PMC3405041?pdf=render |